and the imatinib era. This was independent of the time point of analysis at diagnosis or during follow-up under TKI treatment. This suggests that the pathways of Ph þ clonal evolution are independent from the effects of TKIs. Apparently, TKIs do not seem to select specific Philadelphia cytogenetic alterations. This differs from previous observations in recipients of allogeneic stem cell transplantation (SCT), as differences in the cytogenetic evolution patterns had been observed compared with patients who received conventional treatment. In the study of Karrman et al., 7 there was a lower frequency of major route abnormalities in recipients of allogeneic SCT (15%) when compared with those patients having received an autologous SCT (two from three patients with Ph þ clones). Chase et al. 8 reported a high frequency of translocations and deletions involving 13q in recipients of allo-SCT who showed relapse or persistent disease. Therefore, allo-SCT seems to alter the biology in the Ph þ clones in patients with relapsing or persistent CML, whereas TKIs have no such effect and do not interfere with the pathways of Ph þ clonal evolution. Finally, this study also analyzes the potential of novel visualizing tools to pick up patterns of cytogenetic alterations in hundreds of patients paving the way to new insights into the genetic pathways in leukemias. Myelodysplastic syndrome (MDS) refers to a heterogeneous group of clonal disorders characterized by an impaired hematopoiesis and a variable risk of transformation to acute leukemia. Until lately, most patients have been managed with supportive care, but recent advances in understanding the pathogenesis of MDS have led to innovative therapies for certain subgroups. An inverse relationship was reported between maximum serum ferritin concentration during follow-up and median overall survival. 1 Nevertheless, whether iron overload is a surrogate marker of the severity of the disease or affects the outcome independently by end-organ damage is still controversial. 2 Tefferi and Stone 3 expressed, in a recent Editorial in this Journal, their concerns about the true weight of iron overload in the survival of MDS patients.
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The clinical and biological heterogeneity of MDS makes it difficult to control for differences while designing or analyzing research, particularly in retrospective studies. The aim of this study was to determine whether high levels of serum ferritin are independently associated with a shorter survival in MDS patients, by carefully adjusting for possible susceptibility biases through statistical adjustment and stratification models.
Between January 1992 and March 2009, 268 patients were diagnosed with MDS. We excluded patients who underwent intensive chemotherapy (n ¼ 35), or responded to erythropoietin treatment (n ¼ 23) or iron chelation (n ¼ 11) (whose survival, transfusion requirements and serum ferritin levels could be altered). We also excluded those patients without, at least, a serum ferritin determination during the follow-up (n ¼ 23). One hundred and seventy-six patients fulfilled the inclusion criteria and remained for analysis. In each patient the following variables were examined as possible prognostic factors: age, gender, International Prognostic Scoring System (IPSS) score, platelet mass, lactate dehydrogenase (LDH) levels, development of transfusion requirement and maximum ferritin level reached through follow-up. We considered ferritin levels during the outpatient follow-up, not taking into account determinations performed during hospital admissions, to avoid a measurement bias of ferritin as an acute-phase reactant. Statistical analysis was performed using SPSS 15.0 (SPSS, Chicago, IL, USA) except for statistical power, which was calculated by using GraphPad Statmate 2.0 (GraphPad, San Diego, CA, USA).
The median patient age was 74 years (interquartile range (IQR) 65-79 years), with a male predominance (56%, n ¼ 98). The median follow-up was 22 months (range 1-71 months). Of these patients, 28 (16%) transformed to acute myelogenous leukemia, and 103 (58%) had died by the end of the study. The median survival time was 39 months (IQR 17-79 months). In all, 70 (39%) patients had a refractory anemia (RA), 22 (13%) RA and ringed sideroblasts, 62 (35%) RA with excess of blasts and 22 (13%) non-proliferative chronic myelomonocytic leukemia. The median ferritin level was 538 ng/ml (IQR 229-993 ng/ ml) and 48 (27%) patients reached the maximum ferritin level of 41000 ng/ml during follow-up. One hundred and thirty (70%) patients received, at least, a red blood cell transfusion.
At univariate analysis, the variables associated with a shorter survival (Po0.05) were low platelet mass, older age, high LDH level, developing transfusion requirements, a high IPSS score and a maximum serum ferritin level during follow-up of 41000 ng/ml (Figure 1a) .
Multivariate adjustment
In the first multivariate model we incorporated those variables with values of Pp0.150 in univariate analysis, but excluding transfusion dependency and the IPSS. Ferritin levels and a low platelet mass remained significant (Table 1 ). In the second multivariate model we included the development of transfusion requirements, which showed its significant value. A low platelet mass was not significant, although a trend was noted. In contrast, maximum ferritin level failed to be a significant factor. In the third multivariate Cox regression we added the IPSS score, which was the only independent prognostic factor in this final model. We explored other maximum ferritin level thresholds (41500, 42000, 42500 ng/ml), not reaching the independent significance in any case if transfusion requirement or IPSS score were added. As expected, age was independently related with a shorter survival in the three models.
Stratification adjustment
Based on the previous results, a concern was raised over whether the suitable cohort for studying the prognostic value of iron overload should exclusively include those patients exposed to that potential prognostic factor, that is, those patients who had been transfused.
Among the 130 cohort patients who received at least a red blood cell transfusion, a maximum ferritin level during followup 41000 ng/ml failed to show a significant association with a shorter survival, even in univariate analysis (Figure 1b) . Although retrospectively assessed, this analysis showed a statistical power of 80% to detect a 52% increase in the Abbreviations: CI, confidence interval; HR, hazards ratio; LDH, lactate dehydrogenase; NS, not significant.
Letters to the Editor relative risk of death (a ¼ 0.05). We also explored other maximum ferritin level thresholds (41500, 42000, 42500 ng/ml) without reaching a significant association. The IPSS score was the only independent variable in this subset of patients (HR 1.6 (1.2-2.1, 95% CI), Pp0.001).
In a sample of 176 MDS patients, treated only with supportive care, multivariate Cox regression analysis showed that the IPSS was the only independent prognostic variable on survival, among another six clinical and laboratory variables. In addition, ferritin levels failed to show an independent impact on survival either after multivariate adjustment or after transfusion requirement cohort stratification.
The IPSS score remained a valuable prognostic tool in our series, even after adjusting for some prognostic factors that were not considered when it was designed. 4 Contrary to other proposed scores, IPSS variables were already present at diagnosis, making therapeutic planning and patient counseling accurate at baseline. The latter, together with the IPSS validation in numerous studies (including ours), further supports its priority use in MDS patient management and clinical trials. This is a negative study, as our main hypothesis (that high ferritin levels independently worsen survival in MDS patients) has not been validated. However, we consider that our work has a crucial lesson: not adjusting for transfusion requirement or disease aggressiveness may lead to an incorrect association. Susceptibility bias occurs when groups of patients assembled for a study differ in ways other than the factor in question. These extraneous factors, not the particular factors being analyzed, may determine the outcome. 5 Biases that produce confusion require the concurrence of two phenomena: a particular effectmodifying factor that alters the outcome of the event and a substantially unequal distribution in subgroups among the cohort. 6 Dysplasia is heterogeneously distributed through the MDS spectrum and its intensity clearly affects transfusion requirement, and consequently, iron overload.
We acknowledge that there are several limitations to our study. First, this is a retrospective study and serum ferritin levels were not routinely determined through follow-up. It explains the exclusion of 23 patients owing to ferritin missing data, most of them (95%) before 2003, reflecting the emerging concerns about iron overload in the last years in the MDS field. Second, serum ferritin has the properties of an acute-phase reactant, and this fact may represent a measurement bias. We attempted to minimize the concerns about this effect by not considering serum ferritin levels determined in the context of processes or surgical procedures that needed hospital admission. Finally, the exclusion of 11 patients who received iron-chelation therapy, although obviously needed, may imply a selection bias itself. However, it is our opinion that the exclusion of those 11 patients does not distort our conclusions as the median time from diagnosis to the beginning of chelation therapy was scarcely inferior (median 31 months, IQR 19-46 months) to the whole cohort's median survival time (median 39 months, IQR 17-79 months).
MDSs include entities with different clinical course and biological basis, in which planned precautions to avoid confounding (prospective clinical trials) must overcome remedial adjustments in prognostic studies.
Genomic and expression analyses of human B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have uncovered several oncogenic events that contribute to the transformation of B-cell progenitors.
1 Besides BCR-ABL1, mutations and rearrangements detected in BCP-ALL predominantly affect genes coding for transcriptional regulators involved in the control of early hematopoietic differentiation, B-cell development or both. Activating mutations in the JAK2 gene that targets the R683 residue [2] [3] [4] have been recently suggested to cooperate with the transcriptional activation of the gene coding for the cytokine receptor chain gene TSLPR/CRLF2.
5 TSLPR codes for a cytokine receptor chain related to gc/IL2Rc. Both chains are able to interact with IL7R to constitute the receptor for IL7 (gc þ IL7R) or TSLP (TSLPR þ IL7R). Signaling from the IL7 receptor is known to involve JAK1 and JAK3 whereas intracellular signaling by the TSLP receptor is poorly characterized. 6 In BCP-ALL, aberrant expression of TSLPR itself occurs through either a cryptic chromosomal translocation between the TSLPR locus (Xp22/ Yp11) and the immunoglobulin heavy-chain locus (14q32) or through a deletion of chromosome X or Y pseudoautosomal sequences juxtaposing the P2RY8 gene to TSLPR.
5 Sox5 upregulation through juxtaposition to the P2RY8 promoter has been previously reported in lymphoma.
